RxDoctor Payments Data

Desmond Jackson, MD

Rheumatology · Waterford, MINPI 1043650765

Payments from drug & device makers

$3,342in general payments, 2019–2025

Across 264 payments — averaging $12.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • AbbVie$752
  • Amgen$509
  • Pfizer$338
  • Novartis$222
  • UCB, Inc.$74
  • plus $196 from 7 others

What the payments were for

  • Food & beverage$3,27798%
  • Education$652%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)124$1,251
AbbVie62$752
Amgen(2 entities)27$509
Pfizer26$338
Novartis11$222
UCB, Inc.4$74
AstraZeneca(2 entities)3$62
Lilly USA, LLC2$38
Radius Health, Inc.1$24
Bristol Myers Squibb1$21
GSK1$19
Regeneron Healthcare Solutions, Inc.1$18
E.r. Squibb & Sons, L.L.C.1$15

How this compares

$3,342 in reported general payments places this provider in the 50th percentile of 195 rheumatology providers in Michigan.

See all rheumatology providers in Michigan

Medicare billing

Part B allowed, 2024
$31,732
Medicare patients
139
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab55$500,401
Enbrel SureclickEtanercept60$463,084
Xeljanz XrTofacitinib Citrate37$221,665
RinvoqUpadacitinib30$206,196
OtezlaApremilast41$196,461
Humira PenAdalimumab13$168,989
KevzaraSarilumab15$93,086
HumiraAdalimumab13$87,960
Cyltezo(Cf) PenAdalimumab-Adbm12$74,128
Actemra ActpenTocilizumab15$72,929
XeljanzTofacitinib Citrate12$66,466
Hydroxychloroquine Sulfate385$17,855
MethotrexateMethotrexate Sodium243$9,032
Methylprednisolone112$5,264
Prednisone400$4,222

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira$752$294,15643 claims
AmgenOtezla$509$196,46141 claims
PfizerXeljanz$338$66,46612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 195 rheumatology providers in Michigan.

Other rheumatology in Waterford

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →